Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC17658GuggulsteroneCAS: 95975-55-6纯度: >99.50%
Guggulsterone是一种从植物Commiphora wightii的树脂中提取的植物甾醇。Guggulsterone可以抑制多种肿瘤细胞的生长,并通过下调抗凋亡基因产物(IAP1、xIAP、Bfl-1/A1、Bcl-2、cFLIP和survivin)、调节细胞周期蛋白(如Cyclin D1和c-Myc)、激活半胱氨酸蛋白酶、抑制Akt以及激活JNK来诱导细胞凋亡。
- GC17694Pemetrexed disodium hemipenta hydrateCAS: 357166-30-4纯度: >99.00%
Pemetrexed disodium hemipenta hydrate 是一种新型抗叶酸剂,LY231514 的五谷氨酸的 Ki 值分别为 1.3、7.2 和 65 nM,用于抑制胸苷酸合酶 (TS)、二氢叶酸还原酶 (DHFR) 和甘氨酰胺核糖核苷酸甲酰转移酶 (GARFT)。
- GC17955Vatalanib (PTK787) 2HClCAS: 212141-51-0纯度: >99.50%
A potent and selective VEGF receptor inhibitor
- GC17995Tacrolimus monohydrateCAS: 109581-93-3纯度: >98.00% / >99.90%
他克莫司一水合物 (FK506 monohydrate) 是一种大环内酯,与 FK506 结合蛋白 (FKBP) 结合形成复合物并抑制钙调神经磷酸酶,从而抑制 T 淋巴细胞信号转导和 IL-2 转录。
- GC18044TrabectedinCAS: 114899-77-3纯度: >99.50%
Trabectedin是一种具有强效抗肿瘤活性的四氢异喹啉生物碱。Trabectedin可选择性抑制与DNA损伤修复相关的转录因子,并阻断DNA核苷酸切除修复通路,导致DNA双链断裂和肿瘤细胞凋亡。Trabectedin还能调节肿瘤微环境,通过抑制肿瘤相关巨噬细胞的活性间接发挥抗肿瘤作用。Trabectedin常用于软组织肉瘤和卵巢癌的研究。
- GC18069CardamoninCAS: 19309-14-9纯度: >98.00%
A chalconoid with anti-inflammatory and anti-tumor activity
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC17658 | Guggulsterone | 95975-55-6 | >99.50% | |
Guggulsterone是一种从植物Commiphora wightii的树脂中提取的植物甾醇。Guggulsterone可以抑制多种肿瘤细胞的生长,并通过下调抗凋亡基因产物(IAP1、xIAP、Bfl-1/A1、Bcl-2、cFLIP和survivin)、调节细胞周期蛋白(如Cyclin D1和c-Myc)、激活半胱氨酸蛋白酶、抑制Akt以及激活JNK来诱导细胞凋亡。 | ||||
| GC17685 | Sildenafil Citrate | 171599-83-0 | >99.50% | |
A PDE5 inhibitor | ||||
| GC17694 | Pemetrexed disodium hemipenta hydrate | 357166-30-4 | >99.00% | |
Pemetrexed disodium hemipenta hydrate 是一种新型抗叶酸剂,LY231514 的五谷氨酸的 Ki 值分别为 1.3、7.2 和 65 nM,用于抑制胸苷酸合酶 (TS)、二氢叶酸还原酶 (DHFR) 和甘氨酰胺核糖核苷酸甲酰转移酶 (GARFT)。 | ||||
| GC17750 | Raltitrexed | 112887-68-0 | >98.50% / >98.00% | |
An inhibitor of thymidylate synthase | ||||
| GC17778 | TAME | 901-47-3 | >98.00% | |
TAME 是后期促进复合物/环体(APC/C 或 APC)的抑制剂,它与 APC/C 结合并阻止其被 Cdc20 和 Cdh1 激活,产生有丝分裂停滞。 TAME 不具有细胞渗透性。 | ||||
| GC17785 | Macitentan | 441798-33-0 | >99.50% / >99.00% | |
A dual ET A /ET B receptor antagonist | ||||
| GC17802 | MK-4827 | 1038915-60-4 | >99.50% / >98.00% | |
MK-4827是具有口服活性的PARP抑制剂,可同时抑制PARP1(IC 50 =3.8nM)和PARP2(IC 50 =2.1nM),MK-4827可抑制PARP酶来阻断DNA修复,诱导癌细胞死亡。 | ||||
| GC17828 | BI-847325 | 1207293-36-4 | >99.00% | |
A selective dual MEK/Aurora kinase inhibitor | ||||
| GC17865 | Lomustine | 13010-47-4 | >99.50% | |
A DNA alkylating agent | ||||
| GC17866 | INCB28060 | 1029712-80-8 | >99.50% | |
INCB28060是一种高效、口服生物利用度高的c-Met抑制剂,其IC₅₀值为0.13nM。INCB28060用于治疗成人转移性非小细胞肺癌(NSCLC),包括Met外显子14跳跃产生的突变变体的NSCLC患者。 | ||||
| GC17881 | AGK 2 | 304896-28-4 | >99.50% | |
AGK2是一种选择性的SIRT2 抑制剂,IC50为3.5 µM。 | ||||
| GC17886 | Stattic | 19983-44-9 | >98.00% | |
Stattic是第一个非肽类小分子STAT3抑制剂,能有效抑制STAT3的激活和核转位。 | ||||
| GC17901 | Tamoxifen | 10540-29-1 | >98.00% / >99.00% | |
Tamoxifen(他莫西芬)是一种选择性雌激素受体调节剂 (SERM),可阻断乳腺细胞中的雌激素作用,并可激活不同组织细胞中的雌激素活性;Tamoxifen 还可以作为 Hsp90 激活剂,增强 Hsp90 分子伴侣 ATPase 的活性;Tamoxifen 还可以诱导 CreER(T2) 小鼠的基因敲除。 | ||||
| GC17916 | Poziotinib | 1092364-38-9 | - | |
An inhibitor of EGFRs | ||||
| GC17918 | Capsazepine | 138977-28-3 | >99.00% | |
Capsazepine是瞬时受体电位香草素1(TRPV1)受体的特异性拮抗剂,IC 50 值为562 nM。 | ||||
| GC17943 | PD173074 | 219580-11-7 | >99.50% / >98.00% | |
PD173074是一种ATP竞争性FGFR1和VEGFR2抑制剂,IC 50 值分别为26nM和100-200nM,对FGFR1的选择性高于PDGFR和c-Src。 | ||||
| GC17955 | Vatalanib (PTK787) 2HCl | 212141-51-0 | >99.50% | |
A potent and selective VEGF receptor inhibitor | ||||
| GC17958 | Linifanib (ABT-869) | 796967-16-3 | >98.00% | |
A dual VEGFR and PDGFR family kinase inhibitor | ||||
| GC17990 | PP 1 | 172889-26-8 | >98.50% | |
PP 1是一种新型的高效、选择性Src家族酪氨酸激酶抑制剂,PP 1有效抑制Lck(IC 50 =5nM)和Fyn(IC 50 =6nM)的磷酸化来阻断T细胞受体信号通路。 | ||||
| GC17995 | Tacrolimus monohydrate | 109581-93-3 | >98.00% / >99.90% | |
他克莫司一水合物 (FK506 monohydrate) 是一种大环内酯,与 FK506 结合蛋白 (FKBP) 结合形成复合物并抑制钙调神经磷酸酶,从而抑制 T 淋巴细胞信号转导和 IL-2 转录。 | ||||
| GC18008 | PCI-34051 | 950762-95-5 | >99.00% | |
PCI-34051是一种高效且选择性的HDAC8抑制剂,其IC 50 为10nM。 | ||||
| GC18021 | Ac-YVAD-CHO | 143313-51-3 | >98.50% | |
An inhibitor of caspase-1 | ||||
| GC18044 | Trabectedin | 114899-77-3 | >99.50% | |
Trabectedin是一种具有强效抗肿瘤活性的四氢异喹啉生物碱。Trabectedin可选择性抑制与DNA损伤修复相关的转录因子,并阻断DNA核苷酸切除修复通路,导致DNA双链断裂和肿瘤细胞凋亡。Trabectedin还能调节肿瘤微环境,通过抑制肿瘤相关巨噬细胞的活性间接发挥抗肿瘤作用。Trabectedin常用于软组织肉瘤和卵巢癌的研究。 | ||||
| GC18069 | Cardamonin | 19309-14-9 | >98.00% | |
A chalconoid with anti-inflammatory and anti-tumor activity | ||||
